Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787303 · ClinicalTrials.gov registry record · Phase 2
Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
A Phase 2 study, sponsored by Aultman Health Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03787303 is a Phase 2 study that was terminated before completion, run by Aultman Health Foundation. The registered enrollment target is 7 participants.
The verdict
NCT03787303, a Phase 2 study, was terminated before completion, sponsored by Aultman Health Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may have benefits in preventing disease progression over l-thyroxine (T4).
Interventions
- DRUG Triiodothyronine (T3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03787303
The ClinicalTrials.gov registry entry for NCT03787303 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aultman Health Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triiodothyronine (T3) is the first listed.
NCT03787303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03787303 about?
NCT03787303 is a clinical study titled "Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma". Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may have benefits in preventing diseas...
What is the current status of trial NCT03787303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-03-01. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03787303?
The interventions under investigation include: Triiodothyronine (T3) (DRUG).
Who is sponsoring clinical trial NCT03787303?
This trial is sponsored by Aultman Health Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.